CardioGenics (CGNH) 10-Q 23 Sep 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jul. 31, 2015	Sep. 18, 2015
Document And Entity Information
Entity Registrant Name	CardioGenics Holdings Inc.
Entity Central Index Key	1,089,029
Document Type	10-Q
Document Period End Date	Jul. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock Shares Outstanding		80,566,160
Trading Symbol	CGNH
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jul. 31, 2015	Oct. 31, 2014
Current assets:
Cash and cash equivalents	$ 49,240	$ 70,276
Accounts Receivable	196	228
Refundable Taxes Receivable	2,465	2,625
Total current assets	51,901	73,529
Property and Equipment, net	36,740	42,693
Deposits and Prepaid Expenses	41,567	45,576
Patents, net	104,740	108,132
Totals	234,948	269,930
Current liabilities:
Accounts Payable and Accrued Expenses	981,199	1,020,809
Funds Held in Trust for Redemption of Class B Common Shares	4	4
Due to Shareholders	107,645	131,052
Notes Payable, net of debt discount	133,843	71,863
Derivative Liability on Notes Payable	645,594	201,260
Total current liabilities and total liabilities	$ 1,868,285	$ 1,424,988
Commitments and contingencies
Deficiency
Preferred stock; par value $.0001 per share, 50,000,000 shares authorized, none issued
Common stock; par value $.00001 per share; 150,000,000 shares authorized, 76,060,520 and 47,383,379 common shares and 24,176,927 and 24,176,927 exchangeable shares issued and outstanding as of July 31, 2015 and October 31, 2014	$ 979	$ 692
Additional paid-in capital	47,400,545	46,505,954
Accumulated deficit	(49,186,943)	(47,637,746)
Accumulated other comprehensive loss	152,082	(23,958)
Total deficiency	(1,633,337)	(1,155,058)
Totals	$ 234,948	$ 269,930

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2015	Oct. 31, 2014
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	76,060,520	47,383,379
Common stock, shares outstanding	76,060,520	47,383,379
Exchangeable Shares [Member]
Common stock, shares issued	24,176,927	24,176,927
Common stock, shares outstanding	24,176,927	24,176,927

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014
Income Statement [Abstract]
Revenue
Operating Expenses
Depreciation and Amortization of Property and Equipment	$ 2,061	$ 2,740	$ 5,953	$ 8,168
Amortization of Patent Application Costs	788	1,724	5,449	5,140
General and Administrative	46,626	107,751	262,141	375,796
Research and Product Development, Net of Investment Tax Credits	50,430	85,241	186,867	275,916
Total operating expenses	99,905	197,456	460,410	665,020
Operating Loss	(99,905)	(197,456)	(460,410)	(665,020)
Other Expenses (Income)
Interest Expense and Bank Charges (Net)	130,118	142,256	392,511	379,836
Loss on Change in Fair Value of Derivative Liability	314,345	246,430	643,194	247,249
Loss (Gain) on Foreign Exchange Transactions	67,122	(20,515)	53,082	21,664
Total other expenses(income)	511,585	368,171	1,088,787	648,749
Net Loss	$ (611,490)	$ (565,627)	$ (1,549,197)	$ (1,313,769)
Basic and Fully Diluted Net Loss per Common Share Shareholders	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted-average shares of Common Stock outstanding	98,626,734	60,938,316	86,990,095	60,260,456

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014
Statement of Comprehensive Income [Abstract]
Net (loss)	$ (611,490)	$ (565,627)	$ (1,549,197)	$ (1,313,769)
Other comprehensive income (loss), currency translation adjustments	105,653	(10,262)	176,040	66,415
Comprehensive (loss)	$ (505,837)	$ (575,889)	$ (1,373,157)	$ (1,247,354)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Changes in Deficiency (Unaudited) - USD ($)	3 Months Ended	9 Months Ended
	Jul. 31, 2015	Jul. 31, 2015
Common Stock [Member]
Balance		$ 692
Balance, shares		71,560,306
Issuance of common shares on conversion of notes payable November 2014		$ 6
Issuance of common shares on conversion of notes payable November 2014, shares		589,679
Issuance of common shares on conversion of notes payable December 2014		$ 30
Issuance of common shares on conversion of notes payable December 2014, shares		2,977,637
Issuance of common shares on conversion of notes payable January 2015		$ 73
Issuance of common shares on conversion of notes payable January 2015, shares		7,349,902
Issuance of common shares on conversion of shareholder's loan February 2015		$ 2
Issuance of common shares on conversion of shareholder's loan February 2015, shares		227,273
Issuance of common shares on conversion of notes payable February 2015		$ 47
Issuance of common shares on conversion of notes payable February 2015, shares		4,684,409
Issuance of common shares on conversion of notes payable March 2015		$ 29
Issuance of common shares on conversion of notes payable March 2015, shares		3,039,913
Issuance of common shares for services rendered March 2015		$ 3
Issuance of common shares for services rendered March 2015, shares		250,000
Issuance of common shares on conversion of notes payable April 2015		$ 7
Issuance of common shares on conversion of notes payable April 2015, shares		718,390
Issuance of common shares on conversion of notes payable May 2015		$ 59
Issuance of common shares on conversion of notes payable May 2015, shares		5,894,104
Issuance of common shares on conversion of notes payable June 2015		$ 15
Issuance of common shares on conversion of notes payable June 2015, shares		1,345,834
Issuance of common shares for cash May 2015		$ 16
Issuance of common shares for cash May 2015, shares		1,600,000
Settlement of derivative value of notes payable on conversion to common shares
Net Loss
Currency Translation Adjustment
Total Comprehensive Income (Loss)
Balance	$ 979	$ 979
Balance, shares	100,237,447	100,237,447
Additional Paid-In Capital [Member]
Balance		$ 46,505,954
Issuance of common shares on conversion of notes payable November 2014		22,528
Issuance of common shares on conversion of notes payable December 2014		32,230
Issuance of common shares on conversion of notes payable January 2015		83,051
Issuance of common shares on conversion of shareholder's loan February 2015		22,854
Issuance of common shares on conversion of notes payable February 2015		40,995
Issuance of common shares on conversion of notes payable March 2015		23,525
Issuance of common shares for services rendered March 2015		7,497
Issuance of common shares on conversion of notes payable April 2015		10,720
Issuance of common shares on conversion of notes payable May 2015		51,301
Issuance of common shares on conversion of notes payable June 2015		18,470
Issuance of common shares for cash May 2015		39,984
Settlement of derivative value of notes payable on conversion to common shares		$ 541,436
Net Loss
Currency Translation Adjustment
Total Comprehensive Income (Loss)
Balance	$ 47,400,545	$ 47,400,545
Accumulated Deficit [Member]
Balance		$ (47,637,746)
Issuance of common shares on conversion of notes payable November 2014
Issuance of common shares on conversion of notes payable December 2014
Issuance of common shares on conversion of notes payable January 2015
Issuance of common shares on conversion of shareholder's loan February 2015
Issuance of common shares on conversion of notes payable February 2015
Issuance of common shares on conversion of notes payable March 2015
Issuance of common shares for services rendered March 2015
Issuance of common shares on conversion of notes payable April 2015
Issuance of common shares on conversion of notes payable May 2015
Issuance of common shares on conversion of notes payable June 2015
Issuance of common shares for cash May 2015
Settlement of derivative value of notes payable on conversion to common shares
Net Loss		$ (1,549,197)
Currency Translation Adjustment
Total Comprehensive Income (Loss)		$ (1,549,197)
Balance	(49,186,943)	(49,186,943)
Accumulated Other Comprehensive Income (Loss) [Member]
Balance		$ (23,958)
Issuance of common shares on conversion of notes payable November 2014
Issuance of common shares on conversion of notes payable December 2014
Issuance of common shares on conversion of notes payable January 2015
Issuance of common shares on conversion of shareholder's loan February 2015
Issuance of common shares on conversion of notes payable February 2015
Issuance of common shares on conversion of notes payable March 2015
Issuance of common shares for services rendered March 2015
Issuance of common shares on conversion of notes payable April 2015
Issuance of common shares on conversion of notes payable May 2015
Issuance of common shares on conversion of notes payable June 2015
Issuance of common shares for cash May 2015
Settlement of derivative value of notes payable on conversion to common shares
Net Loss
Currency Translation Adjustment		$ 176,040
Total Comprehensive Income (Loss)		176,040
Balance	152,082	152,082
Balance		(1,155,058)
Issuance of common shares on conversion of notes payable November 2014		22,534
Issuance of common shares on conversion of notes payable December 2014		32,260
Issuance of common shares on conversion of notes payable January 2015		83,124
Issuance of common shares on conversion of shareholder's loan February 2015		22,856
Issuance of common shares on conversion of notes payable February 2015		41,042
Issuance of common shares on conversion of notes payable March 2015		23,554
Issuance of common shares for services rendered March 2015		7,500
Issuance of common shares on conversion of notes payable April 2015		10,727
Issuance of common shares on conversion of notes payable May 2015		51,360
Issuance of common shares on conversion of notes payable June 2015		18,485
Issuance of common shares for cash May 2015		40,000
Settlement of derivative value of notes payable on conversion to common shares		541,436
Net Loss	(611,490)	(1,549,197)
Currency Translation Adjustment	105,653	176,040
Total Comprehensive Income (Loss)	(505,837)	(1,373,157)
Balance	$ (1,633,337)	$ (1,633,337)

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014
Cash flows from operating activities:
Consolidated net income (loss)	$ (1,549,197)	$ (1,313,769)
Adjustments to reconcile consolidated net income (loss) to net cash used in operating activities:
Depreciation and amortization	5,953	8,168
Amortization of Patent Application Costs	5,449	5,140
Loss on Change in Value of Derivative Liability	643,194	247,249
Interest and Discount on Notes Payable	$ 376,248	123,521
Amortization of Discount on Debentures Payable		186,489
Common stock issued for services rendered	$ 7,500	25,000
Changes in working capital items:
Accounts receivable	32	10
Deposits and Prepaid Expenses	(1,241)	2,094
Refundable Taxes Receivable	$ 160	(580)
Government Grants and Investment Tax Credits Receivable		(11,218)
Accounts Payable and Accrued Expenses	$ 38,416	186,909
Cash used in operating activities	(473,486)	$ (540,987)
Cash flows from investing activities:
Patent Application Costs	(2,057)
Cash used in investing activities	$ (2,057)
Cash flows from financing activities:
Due to Shareholders		$ 22,957
Payment on Notes Payable	$ (4,291)
Proceeds from Notes Payable	255,000	$ 180,000
Issue of Common Shares for Cash	40,000	50,000
Cash provided by financing activities	290,709	252,957
Effects of exchange rate changes on cash	163,798	39,284
Net decrease in cash and cash equivalents	(21,036)	(248,746)
Cash and cash equivalents, beginning of period	70,276	263,103
Cash and cash equivalents, end of period	$ 49,240	$ 14,357

Nature of Business

Nature of Business	9 Months Ended
	Jul. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. Nature of Business CardioGenics Inc. (“CardioGenics”) was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development. CardioGenics’ revenues, to date, have been primarily comprised of grant revenue and Scientific Research Tax Credits from government agencies. There can be no assurance that the Company will be successful in obtaining regulatory approval for the marketing of any of the existing or future products that the Company will succeed in developing. On October 27, 2009, the name of the Company was changed from JAG Media Holdings, Inc. to CardioGenics Holdings, Inc.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jul. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	2. Basis of Presentation In the opinion of management, the unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the condensed interim consolidated financial position of CardioGenics Holdings Inc. and its subsidiaries under generally accepted accounting principles in the United States (“US GAAP”) as of July 31, 2015, their results of operations for the three and nine months ended July 31, 2015 and 2014, changes in deficiency for the nine months ended July 31, 2015 and cash flows for the nine months ended July 31, 2015 and 2014. CardioGenics Holdings Inc. and its subsidiaries are referred to together herein as the “Company”. Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these consolidated financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements, notes to consolidated financial statements and the other information in the audited consolidated financial statements of the Company as of October 31, 2014 and 2013 (the “Audited Financial Statements”) included in the Company’s Form 10-K that was previously filed with the SEC on February 12, 2015 and from which the October 31, 2014 consolidated balance sheet was derived. The results of the Company’s operations for the nine months ended July 31, 2015 are not necessarily indicative of the results of operations to be expected for the full year ending October 31, 2015. The accompanying condensed interim consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at July 31, 2015 of approximately $49.2 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements, management’s plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing. While the Company believes it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Jul. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies. Derivative Instruments The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date. Beneficial Conversion Charge The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values.

Income Taxes

Income Taxes	9 Months Ended
	Jul. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	4. Income Taxes Based on the Company’s evaluation, management has concluded that there are no significant tax positions requiring recognition in the condensed interim consolidated financial statements. The Company has incurred losses in Canada since inception, which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of July 31, 2015 approximated $7,561,000 which will expire from 2015 through 2033. All fiscal years as originally filed have been assessed. Claims relating to research and development credits are open for review for the fiscal years ended October 2014 and 2013. A research and development tax credit for 2012 for which the Company received a refund of $81,460 is being refuted by Canadian taxation authorities. The Company is disputing the position taken by the taxation authorities, but has established a reserve against possible repayment. Returns for the years 2008 through 2014 are yet to be filed. As of July 31, 2015, the Company believes it has net operating loss carryforwards from US sources of approximately $46,927,000 available to reduce future Federal taxable income which will expire from 2020 through 2033. For the nine months ended July 31, 2015 and 2014, the Company’s effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.

Notes Payable

Notes Payable	9 Months Ended
	Jul. 31, 2015
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable On November 19, 2012, the Company entered into an agreement (“Line”) with JMJ Financial (“Lender”) whereby the Company may borrow up to $350,000 from the Lender in increments of $50,000. The Line is subject to an original issue discount of $50,000. Advances under the Line (“Notes”) have a maturity date of one year from the date of the advance. If the advance is repaid within three months, the advance is interest free. If not repaid within three months, the advance may not be repaid before maturity and carries interest at 5%. The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion. Unless agreed in writing by the parties, at no time will the Lender convert any amount owing under the Line into common stock that would result in the Lender owing more than 4.99% of the common stock outstanding. On May 23, 2014, the Company issued promissory notes (the “LG Notes”) to LG Capital Funding, LLC and Adar Bays, LLC (collectively the “Holders”) in the amount of $52,500 each bearing interest at 8% annually due May 23, 2015. The LG Notes and accrued interest may be converted into shares of the Common Stock of the Company at a 42% discount to the lowest closing bid with a 12 day look back. The LG Notes may be prepaid with the following penalties: (i) if the Notes are prepaid within 60 days of the issue date, then at 130% of the face amount plus any accrued interest; and, (ii) if the LG Notes are prepaid after 60 days after the issue date but less than 181 days after the issue date, then at 140% of the face amount plus any accrued interest. The LG Notes may not be prepaid after the 180 th On November 12, 2014, the Company received $50,000 from Chicago Ventures in exchange for a note payable bearing interest at 10% due in one year, convertible into shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 15 days. On November 20, 2014, the Company reached a settlement with IBC Funds, LLC (“IBC”) whereby IBC agreed to pay $78,026 of the Company’s debts in exchange for the right to purchase shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 15 days. On December 15, 2014, the Company received $52,500 from LG Capital in exchange for a note payable bearing interest at 8% due in one year, convertible into shares in the Company’s common stock at a 42% discount from the lowest closing price of the common shares over the prior 15 days. On March 5, 2015, the Company received $55,250 from Actus Private Equity Fund, LLC in exchange for a note payable bearing interest at 8% due November 26, 2015, convertible into shares in the Company’s common stock at a 40% discount from the average of the lowest two trading prices of the common shares over the prior 10 trading days. On July 31, 2015, the Company received $52,500 from Adar Bays in exchange for a note payable bearing interest at 8% due in nine months, convertible into shares in the Company’s common stock at a 45% discount from the lowest closing price of the common shares over the prior 15 days. A summary of the Notes Payable at July 31, 2015 and October 31, 2014 follows: July 31, 2015 October 31, 2014 Convertible Note Payable, due February 20, 2015 $ - $ 12,529 Convertible Notes Payable, due May 23, 2015 - 105,000 Convertible Note Payable, due June 23, 2016 21,449 40,000 Convertible Note Payable, due October 22, 2015 35,000 35,000 Convertible Note Payable, due November 12, 2015 35,000 - Convertible IBC Funds, LLC Payable, due November 21, 2015 16,421 - Convertible Note Payable, due December 15, 2015 26,500 - Convertible Note Payable, due November 26, 2015 55,250 - Convertible Note Payable, due March 25, 2016 23,000 - Convertible Note Payable, due July 31, 2016 55,250 Debt Discount - value attributable to conversion feature attached to Notes, net of accumulated amortization of $133,843 and $71,863 (134,027 ) (120,666 ) Total 133,843 71,863 Less: Current portion 133,843 71,863 Total Long-term portion $ - $ - As described in further detail in Note 6, “Derivative Liabilities”, the Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and as a derivative liability. Upon conversion of the Notes to Common Stock, any remaining unamortized discount is charged to financing expense.

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Jul. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	6. Derivative Liabilities Convertible notes-embedded conversion features: The Notes meet the definition of a hybrid instrument, as defined in ASC 815. The hybrid instrument is comprised of i) a debt instrument, as the host contract and ii) an option to convert the debentures into common stock of the Company, as an embedded derivative. The embedded derivatives derive their value based on the underlying fair value of the Company’s common stock. The embedded derivatives are not clearly and closely related to the underlying host debt instrument since the economic characteristics and risk associated with these derivatives are based on the common stock fair value. The Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and a derivative liability. The Company has recognized a derivative liability of $645,594 at July 31, 2015. Accordingly, changes in the fair value of the embedded derivative are immediately recognized in earnings and classified as a gain or loss on the embedded derivative financial instrument in the accompanying condensed consolidated statements of operations. The Company recognized a loss of $643,194 in the fair value for the nine months ended July 31, 2015. The Company estimated the fair value of the embedded derivatives using a Black Scholes model with the following assumptions: conversion price $0.012 per share according to the agreements; risk free interest rate of .11%; expected life of 1 year; expected dividend of zero; a volatility factor of 249% to 254%, as of July 31, 2015. The expected lives of the instruments are equal to the contractual term of the conversion option. The expected volatility is based on the historical price volatility of the Company’s common stock. The risk-free interest rate represents the U.S. Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Jul. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	7. Fair Value Measurements As defined by the ASC, fair value measurements and disclosures establish a hierarchy that prioritizes fair value measurements based on the type of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of hierarchy are described below: ● Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities. ● Level 2: Inputs other than quoted market prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets, such as interest rates and yield curves that are observable at commonly-quoted intervals. ● Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions, as there is little, if any, related market activity. The following table summarizes the financial liabilities measured at fair value on a recurring basis as of July 31, 2015, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value: Quoted Prices in Total Increase Active Markets for Significant Other Significant in Fair Value Balance Sheet Identical Assets or Observable Inputs Unobservable July 31, 2015 Recorded at Location Liabilities (Level 1) (Level 2) Inputs (Level 3) Total July 31, 2015 Liabilities: Derivative liability – on Notes Payable $ - $ - $ 645,594 $ 645,594 $ 643,194 The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the nine months ended July 31, 2015: 2015 2014 Balance at beginning of period $ 201,260 $ 99,702 Additions to derivative instruments 342,576 180,000 Change in fair value of derivative liabilities 643,194 247,249 Settlements (541,436 ) (98,276 ) Balance at end of period $ 645,594 $ 428,675

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Jul. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Based Compensation	8. Stock Based Compensation Stock-based employee compensation related to stock options for the nine months ended July 31, 2015 and 2014 amounted to $-0-. The following is a summary of the common stock options outstanding, granted, forfeited or expired and exercised under the Plan: Weighted Average Options Exercise Price Outstanding - October 31, 2013 30,000 $ 0.90 Granted - - Forfeited/Expired - - Exercised - - Outstanding - October 31, 2014 30,000 $ 0.90 Granted - - Forfeited/Expired - - Exercised - - Outstanding - July 31, 2015 30,000 $ 0.90 Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at July 31, 2015.

Warrants

Warrants	9 Months Ended
	Jul. 31, 2015
Equity [Abstract]
Warrants	9. Warrants Outstanding warrants are as follows: July 31, 2015 October 31, 2014 Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016 250,000 250,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016 250,000 250,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016 500,000 500,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016 500,000 500,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016 500,000 500,000 Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016 600,000 600,000 Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016 750,000 750,000 Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016 232,500 232,500 Issued to consultants on August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023 2,500,000 2,500,000 Issued to consultants on August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023 1,500,000 1,500,000 Issued to consultant on September 3, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including July 31, 2018 500,000 500,000 Issued to shareholder on October 29, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including October 29, 2016 250,000 250,000 Issued to shareholder on November 7, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016 125,000 - Total Warrants outstanding 8,457,500 8,332,500

Issuance of Common Stock

Issuance of Common Stock	9 Months Ended
	Jul. 31, 2015
Equity [Abstract]
Issuance of Common Stock	10. Issuance of Common Stock During the nine months ended July 31, 2015, the Company issued the following common shares: Issued for cash consideration of $40,000 1,600,000 Issued for services rendered 250,000 Issued to shareholder on conversion of shareholders loan at $0.11 per share 227,273 Issued on conversion of Notes Payable 26,599,868 28,677,141

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Jul. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Share	11. Net Loss per Share The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings (loss) per share (EPS): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Weighted-average shares - basic 98,626,734 60,938,316 86,990,095 60,260,456 Effect of dilutive securities - - - - Weighted-average shares - diluted 98,626,734 60,938,316 86,990,095 60,260,456 Basic earnings (loss) per share “EPS” and diluted EPS for the three and nine months ended July 31, 2015 and 2014 have been computed by dividing the net income (loss) available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants and conversion of debt representing 28,350,458 and 15,367,845 incremental shares, respectively, have been excluded from the three and nine months ended July 31, 2015 and 2014 computation of diluted EPS as they are antidilutive given the net losses generated for the periods presented.

Supplemental Disclosure of Cash

Supplemental Disclosure of Cash Flow Information	9 Months Ended
	Jul. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	12. Supplemental Disclosure of Cash Flow Information For the Nine Months Ended 2015 2014 Cash paid during the year for: Interest $ 16,263 $ 12,352 Income taxes $ - $ - Non-cash financing activities Conversion of notes payable $ 283,086 $ 73,501 Settlement of derivative liability $ 541,436 $ 98,276 Issuance of shares on settlement of suit $ - $ 189,000 Common share issued for services $ 7,500 $ - Common shares issued for shareholder’s loan $ 22,856 $ -

Commitments and Contingent Liab

Commitments and Contingent Liabilities	9 Months Ended
	Jul. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	13. Commitments and contingent liabilities Lawsuit On June 3, 2015, JMJ Financial filed a suit in Florida court demanding payment of its outstanding note payable in the amount of $77,235 for failure to convert a portion of its note into 1,800,000 common shares. The Company has agreed to pay JMJ Financial cash monthly payments of $6,436 over the next eleven months or the equivalent number of common shares at the trading value at the payment due date. A payment of $6,436 was made in July 2015.

Subsequent Events

Subsequent Events	9 Months Ended
	Jul. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events (i) On August 21, 2015 the Company issued JMJ Financial 233,875 common shares in settlement of that month’s obligation under the lawsuit settlement. (ii) On September 15, 2015 the Company issued JMJ Financial 232,860 common shares in settlement of that month’s obligation under the lawsuit settlement.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jul. 31, 2015
Accounting Policies [Abstract]
Derivative Instruments	Derivative Instruments The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date.
Beneficial Conversion Charge	Beneficial Conversion Charge The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values.

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Jul. 31, 2015
Debt Disclosure [Abstract]
Summary of Notes Payable	A summary of the Notes Payable at July 31, 2015 and October 31, 2014 follows: July 31, 2015 October 31, 2014 Convertible Note Payable, due February 20, 2015 $ - $ 12,529 Convertible Notes Payable, due May 23, 2015 - 105,000 Convertible Note Payable, due June 23, 2016 21,449 40,000 Convertible Note Payable, due October 22, 2015 35,000 35,000 Convertible Note Payable, due November 12, 2015 35,000 - Convertible IBC Funds, LLC Payable, due November 21, 2015 16,421 - Convertible Note Payable, due December 15, 2015 26,500 - Convertible Note Payable, due November 26, 2015 55,250 - Convertible Note Payable, due March 25, 2016 23,000 - Convertible Note Payable, due July 31, 2016 55,250 Debt Discount - value attributable to conversion feature attached to Notes, net of accumulated amortization of $133,843 and $71,863 (134,027 ) (120,666 ) Total 133,843 71,863 Less: Current portion 133,843 71,863 Total Long-term portion $ - $ -

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Jul. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Liabilities Measured on Recurring Basis	The following table summarizes the financial liabilities measured at fair value on a recurring basis as of July 31, 2015, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value: Quoted Prices in Total Increase Active Markets for Significant Other Significant in Fair Value Balance Sheet Identical Assets or Observable Inputs Unobservable July 31, 2015 Recorded at Location Liabilities (Level 1) (Level 2) Inputs (Level 3) Total July 31, 2015 Liabilities: Derivative liability – on Notes Payable $ - $ - $ 645,594 $ 645,594 $ 643,194
Schedule of Changes in Fair Value of Financial Liabilities or Derivative Liabilities	The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the nine months ended July 31, 2015: 2015 2014 Balance at beginning of period $ 201,260 $ 99,702 Additions to derivative instruments 342,576 180,000 Change in fair value of derivative liabilities 643,194 247,249 Settlements (541,436 ) (98,276 ) Balance at end of period $ 645,594 $ 428,675

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Jul. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share Based Compensation, Stock Options, Activity	The following is a summary of the common stock options outstanding, granted, forfeited or expired and exercised under the Plan: Weighted Average Options Exercise Price Outstanding - October 31, 2013 30,000 $ 0.90 Granted - - Forfeited/Expired - - Exercised - - Outstanding - October 31, 2014 30,000 $ 0.90 Granted - - Forfeited/Expired - - Exercised - - Outstanding - July 31, 2015 30,000 $ 0.90

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Jul. 31, 2015
Equity [Abstract]
Schedule of Warrants Outstanding	Outstanding warrants are as follows: July 31, 2015 October 31, 2014 Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016 250,000 250,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016 250,000 250,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016 500,000 500,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016 500,000 500,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016 500,000 500,000 Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016 600,000 600,000 Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016 750,000 750,000 Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016 232,500 232,500 Issued to consultants on August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023 2,500,000 2,500,000 Issued to consultants on August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023 1,500,000 1,500,000 Issued to consultant on September 3, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including July 31, 2018 500,000 500,000 Issued to shareholder on October 29, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including October 29, 2016 250,000 250,000 Issued to shareholder on November 7, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016 125,000 - Total Warrants outstanding 8,457,500 8,332,500

Issuance of Common Stock (Table

Issuance of Common Stock (Tables)	9 Months Ended
	Jul. 31, 2015
Equity [Abstract]
Schedule of Common Stock Issue	During the nine months ended July 31, 2015, the Company issued the following common shares: Issued for cash consideration of $40,000 1,600,000 Issued for services rendered 250,000 Issued to shareholder on conversion of shareholders loan at $0.11 per share 227,273 Issued on conversion of Notes Payable 26,599,868 28,677,141

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Jul. 31, 2015
Earnings Per Share [Abstract]
Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share	The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings (loss) per share (EPS): Three Months Ended July 31, Nine Months Ended July 31, 2015 2014 2015 2014 Weighted-average shares - basic 98,626,734 60,938,316 86,990,095 60,260,456 Effect of dilutive securities - - - - Weighted-average shares - diluted 98,626,734 60,938,316 86,990,095 60,260,456

Supplemental Disclosure of Ca29

Supplemental Disclosure of Cash Flow Information (Tables)	9 Months Ended
	Jul. 31, 2015
Supplemental Cash Flow Information [Abstract]
Cash Flow Supplemental Disclosures	For the Nine Months Ended 2015 2014 Cash paid during the year for: Interest $ 16,263 $ 12,352 Income taxes $ - $ - Non-cash financing activities Conversion of notes payable $ 283,086 $ 73,501 Settlement of derivative liability $ 541,436 $ 98,276 Issuance of shares on settlement of suit $ - $ 189,000 Common share issued for services $ 7,500 $ - Common shares issued for shareholder’s loan $ 22,856 $ -

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	Jul. 31, 2015	Oct. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 49,186,943	$ 47,637,746

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014	Oct. 31, 2012
Operating Loss Carryforwards [Line Items]
Income tax benefits
Canadian Taxation Authorities[Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards	$ 7,561,000
Operating loss carry forwards expiration period	from 2015 through 2033
Research and development tax credit refund amount received			$ 81,460
US [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards	$ 46,927,000
Operating loss carry forwards expiration period	from 2020 through 2033

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jul. 31, 2015	Mar. 05, 2015	Dec. 15, 2014	Nov. 20, 2014	Nov. 12, 2014	May. 23, 2014	Nov. 19, 2012	Jul. 31, 2015	Jul. 31, 2014
NotesPayableLineItems [Line Items]
Line of credit facility, maximum borrowing capacity							$ 350,000
Increments in line of credit facility							50,000
Line of credit facility original issue discount							$ 50,000
Line of credit facility, interest rate percentage							5.00%
Lenders right relating to notes payable description							The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion.
Conversion price per share	$ 0.012						$ 0.23	$ 0.012
Debt instrument lowest trading price percentage before conversion							60.00%
Line of credit facility common stock outstanding percentage							4.99%
Debt in exchange to purchase common stock shares								$ 283,086	$ 73,501
LG Capital Funding, LLC and Adar Bays, LLC [Member]
NotesPayableLineItems [Line Items]
Proceeds from issuance of promissory note						$ 52,500
Percentage of promissory notes						8.00%
Debt instrument maturity Date						May 23, 2015
LG Capital Funding [Member]
NotesPayableLineItems [Line Items]
Percentage of debt converted into stock discount						42.00%
Debt penalties below 60 days of issuance						130.00%
Debt penalties After 60 days of issuance						140.00%
Chicago Ventures [Member]
NotesPayableLineItems [Line Items]
Proceeds from issuance of promissory note					$ 50,000
Percentage of promissory notes					10.00%
Percentage of debt converted into stock discount					40.00%
Debt closing price term					15 days
IBC Funds, LLC [Member]
NotesPayableLineItems [Line Items]
Percentage of debt converted into stock discount				40.00%
Debt closing price term				15 days
Debt in exchange to purchase common stock shares				$ 78,026
LG Capital Funding, LLC [Member]
NotesPayableLineItems [Line Items]
Proceeds from issuance of promissory note			$ 52,500
Percentage of promissory notes			8.00%
Percentage of debt converted into stock discount			42.00%
Debt closing price term			15 days
Debt instrument maturity year			1 year
Activus Private Equity Fund, LLC [Member]
NotesPayableLineItems [Line Items]
Proceeds from issuance of promissory note		$ 55,250
Percentage of promissory notes		8.00%
Debt instrument maturity Date		Nov. 26, 2015
Percentage of debt converted into stock discount		40.00%
Debt closing price term		10 days
Adar Bays [Member]
NotesPayableLineItems [Line Items]
Proceeds from issuance of promissory note	$ 52,500
Percentage of promissory notes	8.00%							8.00%
Percentage of debt converted into stock discount	45.00%
Debt closing price term	15 days
Debt instrument maturity year	1 year

Notes Payable - Summary of Note

Notes Payable - Summary of Notes Payable (Details) - USD ($)	Jul. 31, 2015	Oct. 31, 2014
Short-term Debt [Line Items]
Debt Discount - value attributable to conversion feature attached to Notes, net of accumulated amortization of $133,843 and $71,863	$ (134,027)	$ (120,666)
Total	133,843	71,863
Less: Current portion	133,843	$ 71,863
Total Long-term portion	$ 0
Convertible Note Payable, Due February 20, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable		$ 12,529
Convertible Notes Payable, Due May 23, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable		105,000
Convertible Note Payable, Due June 23, 2016 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	$ 21,449	40,000
Convertible Note Payable, Due October 22, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	35,000	$ 35,000
Convertible Note Payable, due November 12, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	35,000
Convertible IBC Funds, LLC Payable, due November 21, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	16,421
Convertible Note Payable, due December 15, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	26,500
Convertible Note Payable, due November 26, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	55,250
Convertible Note Payable, due March 25, 2016 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	23,000
Convertible Note Payable, due July 31, 2016 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	$ 55,250

Notes Payable - Summary of No34

Notes Payable - Summary of Notes Payable (Details) (Parenthetical) - USD ($)	9 Months Ended	12 Months Ended
	Jul. 31, 2015	Oct. 31, 2014
Net of accumulated amortization	$ 133,843	$ 71,863
Convertible Note Payable, Due February 20, 2015 [Member]
Convertible Note Payable, maturity date	Feb. 20, 2015	Feb. 20, 2015
Convertible Notes Payable, Due May 23, 2015 [Member]
Convertible Note Payable, maturity date	May 23, 2015	May 23, 2015
Convertible Note Payable, Due June 23, 2016 [Member]
Convertible Note Payable, maturity date	Jun. 23, 2016	Jun. 23, 2016
Convertible Note Payable, Due October 22, 2015 [Member]
Convertible Note Payable, maturity date	Oct. 22, 2015	Oct. 22, 2015
Convertible Note Payable, due November 12, 2015 [Member]
Convertible Note Payable, maturity date	Nov. 12, 2015	Nov. 12, 2015
Convertible IBC Funds, LLC Payable, due November 21, 2015 [Member]
Convertible Note Payable, maturity date	Nov. 21, 2015	Nov. 21, 2015
Convertible Note Payable, due December 15, 2015 [Member]
Convertible Note Payable, maturity date	Dec. 15, 2015	Dec. 15, 2015
Convertible Note Payable, due November 26, 2015 [Member]
Convertible Note Payable, maturity date	Nov. 26, 2015	Nov. 26, 2015
Convertible Note Payable, due March 25, 2016 [Member]
Convertible Note Payable, maturity date	Mar. 25, 2016	Mar. 25, 2016
Convertible Note Payable, due July 31, 2016 [Member]
Convertible Note Payable, maturity date	Jul. 31, 2016	Jul. 31, 2016

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014	Oct. 31, 2014	Nov. 19, 2012
Derivative liabilities	$ 645,594		$ 645,594		$ 201,260
Loss on change in fair value of derivative liability	$ 314,345	$ 246,430	$ 643,194	$ 247,249
Conversion price per share	$ 0.012		$ 0.012			$ 0.23
Fair value assumptions, risk free interest rate			0.11%
Fair value assumptions, expected term			1 year
Fair value assumptions, expected dividend rate			0.00%
Minimum [Member]
Fair value assumptions, expected volatility rate			249.00%
Maximum [Member]
Fair value assumptions, expected volatility rate			254.00%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Liabilities Measured on Recurring Basis (Details) - USD ($)	9 Months Ended
	Jul. 31, 2015	Oct. 31, 2014
Derivative liability on notes payable	$ 645,594	$ 201,260
Total Increase (Reduction) in Fair Value Recorded	$ 643,194
Quoted Prices In Active Markets For Identical Assets Or Liabilities (Level 1) [Member]
Derivative liability on notes payable
Significant Other Observable Inputs (Level 2) [Member]
Derivative liability on notes payable
Significant Unobservable Inputs (Level 3) [Member]
Derivative liability on notes payable	$ 645,594

Fair Value Measurements - Sch37

Fair Value Measurements - Schedule of Changes in Fair Value of Financial Liabilities or Derivative Liabilities (Details) - USD ($)	9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014
Fair Value Disclosures [Abstract]
Balance at beginning of period	$ 201,260	$ 99,702
Additions to derivative instruments	342,576	180,000
Change in fair value of derivative liabilities	643,194	247,249
Settlements	(541,436)	(98,276)
Balance at end of period	$ 645,594	$ 428,675

Stock Based Compensation (Detai

Stock Based Compensation (Details Narrative) - USD ($)	9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock based employee compensation related to stock options	$ 0	$ 0

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Jul. 31, 2015	Oct. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options, Outstanding beginning balance	30,000	30,000
Options, Granted
Options, Forfeited/Expired
Options, Exercised
Options, Outstanding ending balance	30,000	30,000
Weighted Average Exercise price, Beginning balance	$ 0.90	$ 0.90
Weighted Average Exercise price, Granted
Weighted Average Exercise price, Forfeited/Expired
Weighted Average Exercise price, Exercised
Weighted Average Exercise price, Ending balance	$ 0.90	$ 0.90

Warrants - Schedule of Warrants

Warrants - Schedule of Warrants Outstanding (Details) - shares	Jul. 31, 2015	Oct. 31, 2014
Class of Warrant or Right [Line Items]
Warrants outstanding	8,457,500	8,332,500
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.30 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $1.00 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Debenture Holders February 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.25 Per Common Share Up To And Including February 27, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	600,000	600,000
Issued To Debenture Holders May 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	750,000	750,000
Issued To Debenture Holders June 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	232,500	232,500
Issued To Consultants In August 5, 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	2,500,000	2,500,000
Issued To Consultants In August 5, 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.10 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,500,000	1,500,000
Issued To Consultant In September 3, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including July 31, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Shareholder October 29, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including October 29, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued To Shareholder November 7, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including November 7, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	125,000

Warrants - Schedule of Warran41

Warrants - Schedule of Warrants Outstanding (Details) (Parenthetical) - $ / shares	9 Months Ended	12 Months Ended
	Jul. 31, 2015	Oct. 31, 2014
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.30 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.30	$ 0.30
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.50	$ 0.50
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.75	$ 0.75
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $1.00 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 1	$ 1
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.75	$ 0.75
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued To Debenture Holders February 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.25 Per Common Share Up To And Including February 27, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.25	$ 0.25
Warrant, last exercisable date	Feb. 27, 2016	Feb. 27, 2016
Issued To Debenture Holders May 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.15	$ 0.15
Warrant, last exercisable date	Jun. 3, 2016	Jun. 3, 2016
Issued To Debenture Holders June 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.15	$ 0.15
Warrant, last exercisable date	Jun. 3, 2016	Jun. 3, 2016
Issued To Consultants In August 5, 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.15	$ 0.15
Warrant, last exercisable date	Aug. 4, 2023	Aug. 4, 2023
Issued To Consultants In August 5, 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.10 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.10	$ 0.10
Warrant, last exercisable date	Aug. 4, 2023	Aug. 4, 2023
Issued To Consultant In September 3, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including July 31, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.50	$ 0.50
Warrant, last exercisable date	Jul. 31, 2018	Jul. 31, 2018
Issued To Shareholder October 29, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including October 29, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.15	$ 0.15
Warrant, last exercisable date	Oct. 29, 2016	Oct. 29, 2016
Issued To Shareholder November 7, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including November 7, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.15	$ 0.15
Issued to shareholder November 7, 2013, entitling the holder to purchase 1 common shares in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, last exercisable date	Nov. 7, 2016	Nov. 7, 2016

Issuance of Common Stock - Sche

Issuance of Common Stock - Schedule of Common Stock Issue (Details) - Common Stock [Member]	9 Months Ended
	Jul. 31, 2015shares
Issued for cash consideration of $ 40,000	1,600,000
Issued for services rendered	250,000
Issued to shareholder on conversion of shareholders loan at $0.11 per share	227,273
Issued on conversion of Notes Payable	26,599,868
Number of shares issued during period	28,677,141

Issuance of Common Stock - Sc43

Issuance of Common Stock - Schedule of Common Stock Issue (Details) (Parenthetical) - USD ($)	9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014
Equity [Abstract]
Proceeds from issuance of common stock for cash	$ 40,000	$ 50,000
Equity price per share	$ 0.11

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	3 Months Ended		9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014
Earnings Per Share [Abstract]
Incremental shares excluded from computation of diluted earnings per share	28,350,458	15,367,845	28,350,458	15,367,845

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014
Earnings Per Share [Abstract]
Weighted-average shares - basic	98,626,734	60,938,316	86,990,095	60,260,456
Effect of dilutive securities
Weighted-average shares - diluted	98,626,734	60,938,316	86,990,095	60,260,456

Supplemental Disclosure of Ca46

Supplemental Disclosure of Cash Flow Information - Cash Flow Supplemental Disclosures (Details) - USD ($)	9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash paid during the period for: Interest	$ 16,263	$ 12,352
Cash paid during the period for: Income taxes
Non-cash financing activities: Conversion of Notes Payable	$ 283,086	$ 73,501
Non-cash financing activities: Settlement of derivative liability	$ 541,436	98,276
Non-cash financing activities: Issuance of shares on settlement of suit		$ 189,000
Non-cash financing activities: Common share issued for services	$ 7,500
Non-cash financing activities: Common shares issued for shareholder's loan	$ 22,856

Commitments and Contingent Li47

Commitments and Contingent Liabilities (Details Narrative) - Jun. 03, 2015 - JMJ Financial [Member] - USD ($)	Total
Litigation settlement amount	$ 77,235
Number of common shares failed to convert	1,800,000
Litigation settlement monthly installments	$ 6,436

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - shares	Sep. 15, 2015	Aug. 21, 2015
Subsequent Event [Member] | JMJ Financial [Member]
Number of common shares issued under lawsuit settlement	232,860	233,875